非布索坦治疗效果

Is the treatment with (Febuxostat) effective? Febuxostat, also known as febuxostat, was approved for marketing by the U.S. Food and Drug Administration (FDA) in February 2009. Its indication is for the long-term treatment of patients with gout and hyperuricemia. Febuxostat (Febuxostat) is a new and highly effective non-purine xanthine oxidase selective inhibitor. It has also been approved for marketing in my country, bringing new treatment options to domestic gout patients.

The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid. Febuxostat (Febuxostat) effectively treats gout by acting highly selectively on this oxidase, reducing uric acid synthesis in the body and reducing uric acid concentration.

Since the serum uric acid concentration drops rapidly in the early stage of taking the drug, the uric acid deposited in the tissue can be mobilized, so symptoms similar to a gout attack may occur. In this case, nonsteroidal anti-inflammatory drugs or colchicine can be used for preventive administration.

Febuxostat (febuxostat) has clear advantages over allopurine. Allopurinol only inhibits the reduced form of XOR, while febuxostat (febuxostat) has a significant inhibitory effect on both the oxidized and reduced forms of XOR, so its uric acid-lowering effect is more powerful and lasting; because allopurinol is a purine analogue, it inevitably affects the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. Febuxostat (Febuxostat) is a non-purine XOR inhibitor and therefore has a better safety profile. In the "China Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout (2019)", (Febuxostat) is recommended as the first-line drug for lowering uric acid in patients with gout, and the effect of Febuxostat (Febuxostat) in the treatment of gout should not be underestimated.

Related hot article recommendations: